These preclinical results demonstrate the therapeutic potential of targeting POLΘ in oncogene-driven hematologic cancers, especially in MCL, where cyclin D1 overexpression is ubiquitous and ATM deficiency is common, but may extend to other oncogene-driven hematologic cancers. This evidence concerns the gene ATM and mantle cell lymphoma.